Comparison of the Neutralizing Antibodies’ Ability in Different COVID-19 Vaccine Platforms Recipients

The COVID-19 pandemic has led to great efforts to achieve effective vaccines with different approaches around the world, and different vaccine platforms have been developed against SARSCoV-2. Meanwhile, these technologies are still being investigated to obtain more data on the efficacy of combined vaccine platforms. The purpose of this study is to investigate the power of neutralizing antibodies of vaccinated people against COVID-19 in different vaccination regimens in Iran. We investigated Sinopharm/Sinopharm, Sinopharm/PastoCovac or Plus, AstraZeneca/AstraZeneca and AstraZeneca/ PastoCovac Plus recipients. The sera samples were collected from vaccinated individuals 3 weeks after the booster shots. cVNT test was done on the samples after sera dilution. The results showed that all the vaccine regimens induced neutralizing antibodies. Nevertheless, the combinational vaccine regimens in Sinopharm primed individuals showed greater neutralizing potency comparing to the homologous group. Moreover, PastoCovac Plus showed similar ability to AstraZeneca vaccine regarding neutralizing Wuhan and BA.5 variants.